RXI 109

Drug Profile

RXI 109

Alternative Names: RXI-109

Latest Information Update: 23 Jun 2017

Price : $50

At a glance

  • Originator RXi Pharmaceuticals
  • Class Oligonucleotides; Small interfering RNA; Small molecules
  • Mechanism of Action Connective tissue growth factor inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Keloids; Scars
  • Phase I/II Retinal disorders

Most Recent Events

  • 21 Jun 2017 RXi Pharmaceuticals completes enrolment in a phase I/II trial for Retinal disorders in USA
  • 28 Mar 2017 RXi Pharmaceuticals has patent protection for RXI 109 in Japan
  • 28 Mar 2017 RXi Pharmaceuticals receives patent allowance for RXI 109 in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top